Vazula Bekkers

1. General introduction 32 perspectives. Clin Cosmet Investig Dermatol. 2018;11:387-396. doi:ccid-11-387 [pii]10.2147/CCID.S133672 50. Lemperle G, Schierle J, Kitoga KE, Kassem-Trautmann K, Sachs C, Dimmler A. Keloids: Which Types Can Be Excised without Risk of Recurrence? A New Clinical Classification. Plast Reconstr Surg Glob Open. Mar 2020;8(3):e2582. doi:10.1097/GOX.0000000000002582 51. Robles DT, Berg D. Abnormal wound healing: keloids. Clinics in Dermatology. 2007/01/01/ 2007;25(1):26-32. doi:https://doi.org/10.1016/j.clindermatol.2006.09.009 52. Trisliana Perdanasari A, Torresetti M, Grassetti L, et al. Intralesional injection treatment of hypertrophic scars and keloids: a systematic review regarding outcomes. Burns & Trauma. 2015/08/26 2015;3(1):14. doi:10.1186/s41038-015-0015-7 53. Kim WI, Kim S, Cho SW, Cho MK. The efficacy of bleomycin for treating keloid and hypertrophic scar: A systematic review and meta-analysis. J Cosmet Dermatol. Dec 2020;19(12):3357-3366. doi:10.1111/jocd.13390 54. Umezawa H, Maeda K, Takeuchi T, Okami Y. New antibiotics, bleomycin A and B. J Antibiot (Tokyo). Sep 1966;19(5):200-9. 55. Viera MH, Caperton CV, Berman B. Advances in the treatment of keloids. J Drugs Dermatol. May 2011;10(5):468-80. 56. Mabeta P, Pepper MS. A comparative study on the anti-angiogenic effects of DNAdamaging and cytoskeletal-disrupting agents. Angiogenesis. 2009;12(1):81-90. doi:10.1007/s10456-009-9134-8 57. Bik L, Sangers T, Greveling K, Prens E, Haedersdal M, van Doorn M. Efficacy and tolerability of intralesional bleomycin in dermatology: A systematic review. J Am Acad Dermatol. Sep 2020;83(3):888-903. doi:S0190-9622(20)30226-7 [pii] 10.1016/j.jaad.2020.02.018 58. Hendel K, Hansen ACN, Bik L, et al. Bleomycin administered by laser-assisted drug delivery or intradermal needle-injection results in distinct biodistribution patterns in skin: in vivo investigations with mass spectrometry imaging. Drug Deliv. Dec 2021;28(1):1141-1149. doi:1933649 [pii] 10.1080/10717544.2021.1933649

RkJQdWJsaXNoZXIy MTk4NDMw